tiprankstipranks
Trending News
More News >

Acadia Pharmaceuticals price target raised to $28 from $24 at BMO Capital

BMO Capital raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $28 from $24 and keeps an Outperform rating on the shares after a U.S. District court upheld the validity of the company’s ‘721 patent. Improved IP protection is likely to start to change the narrative around shares, giving investors confidence that Acadia revenue is stable in the long term, the analyst tells investors in a research note.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue